Invasive lobular and ductal breast carcinoma differ in immune response, protein translation efficiency and metabolism

[1]  S. Oesterreich,et al.  Opening the Door for Immune Oncology Studies in Invasive Lobular Breast Cancer. , 2018, Journal of the National Cancer Institute.

[2]  I. Ellis,et al.  Immune Infiltration in Invasive Lobular Breast Cancer , 2018, Journal of the National Cancer Institute.

[3]  Jack Cuzick,et al.  Relevance of Spatial Heterogeneity of Immune Infiltration for Predicting Risk of Recurrence After Endocrine Therapy of ER+ Breast Cancer , 2018, Journal of the National Cancer Institute.

[4]  A. Gonzalez-Perez,et al.  A Pan-cancer Landscape of Interactions between Solid Tumors and Infiltrating Immune Cell Populations , 2017, Clinical Cancer Research.

[5]  Phillip G. Montgomery,et al.  Defining a Cancer Dependency Map , 2017, Cell.

[6]  S. Oesterreich,et al.  Distinct Pattern of Metastases in Patients with Invasive Lobular Carcinoma of the Breast , 2017, Geburtshilfe und Frauenheilkunde.

[7]  B. Ring,et al.  Molecular Classification of Lobular Carcinoma of the Breast , 2017, Scientific Reports.

[8]  Cailin E. Joyce,et al.  Differential Regulation of the Melanoma Proteome by eIF4A1 and eIF4E. , 2017, Cancer research.

[9]  S. Elledge,et al.  Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy , 2017, Science.

[10]  Mupeng Li,et al.  Environmental Research and Public Health New Immunotherapy Strategies in Breast Cancer , 2022 .

[11]  J. Pelletier,et al.  Translation Initiation Factors: Reprogramming Protein Synthesis in Cancer. , 2016, Trends in cell biology.

[12]  H. McArthur,et al.  Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy. , 2016, Clinical advances in hematology & oncology : H&O.

[13]  S. Kurozumi,et al.  Clinical Significance of 18F-FDG-PET in Invasive Lobular Carcinoma. , 2016, Anticancer research.

[14]  P. Campbell,et al.  Genomic Characterization of Primary Invasive Lobular Breast Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Jun S. Liu,et al.  Comprehensive analyses of tumor immunity: implications for cancer immunotherapy , 2016, Genome Biology.

[16]  M. Serin,et al.  Correlation between 18F-FDG Positron-Emission Tomography 18F-FDG Uptake Levels at Diagnosis and Histopathologic and Immunohistochemical Factors in Patients with Breast Cancer. , 2016, The journal of breast health.

[17]  Bin Liu,et al.  Erratum: The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes , 2016, Nature Communications.

[18]  N. Rosenfeld,et al.  The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes , 2016, Nature Communications.

[19]  O. Metzger-Filho,et al.  Differences between invasive lobular and invasive ductal carcinoma of the breast: results and therapeutic implications , 2016, Therapeutic advances in medical oncology.

[20]  Michael L. Gatza,et al.  Proteogenomics connects somatic mutations to signaling in breast cancer , 2016, Nature.

[21]  Y. Kodera,et al.  Comparison of clinical outcomes between luminal invasive ductal carcinoma and luminal invasive lobular carcinoma , 2016, BMC Cancer.

[22]  R. Bernards,et al.  Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer , 2016, Scientific Reports.

[23]  A. Butte,et al.  Systematic pan-cancer analysis of tumour purity , 2015, Nature Communications.

[24]  Andrea Bild,et al.  Alternative preprocessing of RNA-Sequencing data in The Cancer Genome Atlas leads to improved analysis results , 2015, Bioinform..

[25]  Brittany Z Dashevsky,et al.  Comparison of 18F-FDG PET/CT for Systemic Staging of Newly Diagnosed Invasive Lobular Carcinoma Versus Invasive Ductal Carcinoma , 2015, The Journal of Nuclear Medicine.

[26]  Steven J. M. Jones,et al.  Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer , 2015, Cell.

[27]  A. Giobbie-Hurder,et al.  Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  M. Mathieu,et al.  Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  D. Sarma,et al.  Lobular breast cancer series: imaging , 2015, Breast Cancer Research.

[30]  P. Sharma,et al.  Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential , 2015, Cell.

[31]  P. Sharma,et al.  The future of immune checkpoint therapy , 2015, Science.

[32]  Cyrus M. Ghajar.  Metastasis prevention by targeting the dormant niche , 2015, Nature Reviews Cancer.

[33]  N. Sonenberg,et al.  Targeting the translation machinery in cancer , 2015, Nature Reviews Drug Discovery.

[34]  Razelle Kurzrock,et al.  PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy , 2015, Molecular Cancer Therapeutics.

[35]  M. Christgen,et al.  Lobular breast cancer: molecular basis, mouse and cellular models , 2015, Breast Cancer Research.

[36]  Jamie R. Kutasovic,et al.  Invasive lobular carcinoma of the breast: morphology, biomarkers and ’omics , 2015, Breast Cancer Research.

[37]  Matthew E. Ritchie,et al.  limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.

[38]  L. Vatten,et al.  Invasive lobular breast cancer: the prognostic impact of histopathological grade, E-cadherin and molecular subtypes , 2014, Histopathology.

[39]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[40]  S Michiels,et al.  Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[41]  W. Jung,et al.  Expression of metabolism-related proteins in invasive lobular carcinoma: comparison to invasive ductal carcinoma , 2014, Tumor Biology.

[42]  J. Nortier,et al.  Immunological subtypes in breast cancer are prognostic for invasive ductal but not for invasive lobular breast carcinoma , 2014, British Journal of Cancer.

[43]  D. Dabbs,et al.  Invasive lobular carcinoma cell lines are characterized by unique estrogen-mediated gene expression patterns and altered tamoxifen response. , 2014, Cancer research.

[44]  D. Dabbs,et al.  Invasive lobular carcinoma of the breast: Patient response to systemic endocrine therapy and hormone response in model systems , 2013, Steroids.

[45]  Hong Wang,et al.  Translation Initiation Factor eIF3b Expression in Human Cancer and Its Role in Tumor Growth and Lung Colonization , 2013, Clinical Cancer Research.

[46]  J. Stagg,et al.  Immunotherapeutic approaches in triple-negative breast cancer: latest research and clinical prospects , 2013, Therapeutic advances in medical oncology.

[47]  Justin Guinney,et al.  GSVA: gene set variation analysis for microarray and RNA-Seq data , 2013, BMC Bioinformatics.

[48]  G. Mills,et al.  Aberrations in translational regulation are associated with poor prognosis in hormone receptor-positive breast cancer , 2012, Breast Cancer Research.

[49]  H. Kuerer,et al.  Invasive lobular carcinoma predicts micrometastasis in breast cancer. , 2012, The Journal of surgical research.

[50]  B. Van Houten,et al.  Oxidants and not alkylating agents induce rapid mtDNA loss and mitochondrial dysfunction. , 2012, DNA repair.

[51]  D. Ruggero.  Translational control in cancer etiology. , 2012, Cold Spring Harbor perspectives in biology.

[52]  F. Markowetz,et al.  The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.

[53]  S. Leung,et al.  CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer , 2012, Breast Cancer Research.

[54]  John Quackenbush,et al.  A three-gene model to robustly identify breast cancer molecular subtypes. , 2012, Journal of the National Cancer Institute.

[55]  Ian O Ellis,et al.  Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  D. Groheux,et al.  Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[57]  A. Vincent-Salomon,et al.  Lobular invasive carcinoma of the breast is a molecular entity distinct from luminal invasive ductal carcinoma. , 2010, European journal of cancer.

[58]  B. Van Houten,et al.  Alterations in bioenergetics due to changes in mitochondrial DNA copy number. , 2010, Methods.

[59]  Shu Ichihara,et al.  Breast cancer prognostic classification in the molecular era: the role of histological grade , 2010, Breast Cancer Research.

[60]  Yang Liu,et al.  mTOR Regulation and Therapeutic Rejuvenation of Aging Hematopoietic Stem Cells , 2009, Science Signaling.

[61]  D. Sabatini,et al.  mTOR signaling at a glance , 2009, Journal of Cell Science.

[62]  Axel Benner,et al.  Effects of infiltrating lymphocytes and estrogen receptor on gene expression and prognosis in breast cancer , 2009, Breast Cancer Research and Treatment.

[63]  V. Speirs,et al.  Combined analysis of eIF4E and 4E-binding protein expression predicts breast cancer survival and estimates eIF4E activity , 2009, British Journal of Cancer.

[64]  F. Bertucci,et al.  Lobular and ductal carcinomas of the breast have distinct genomic and expression profiles , 2008, Oncogene.

[65]  R. Gelber,et al.  Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  H. Tsuda,et al.  Clinicopathological and prognostic relevance of uptake level using 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in primary breast cancer. , 2008, Japanese journal of clinical oncology.

[67]  V. Mootha,et al.  mTOR controls mitochondrial oxidative function through a YY1–PGC-1α transcriptional complex , 2007, Nature.

[68]  Muriel Brackstone,et al.  Tumour dormancy in breast cancer: an update , 2007, Breast Cancer Research.

[69]  J. P. McCoy,et al.  The Mammalian Target of Rapamycin (mTOR) Pathway Regulates Mitochondrial Oxygen Consumption and Oxidative Capacity* , 2006, Journal of Biological Chemistry.

[70]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[71]  J. Daling,et al.  Clinical characteristics of different histologic types of breast cancer , 2005, British Journal of Cancer.

[72]  David Botstein,et al.  Different gene expression patterns in invasive lobular and ductal carcinomas of the breast. , 2004, Molecular biology of the cell.

[73]  Sven N. Reske,et al.  Biological characterisation of breast cancer by means of PET , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[74]  I. Yang,et al.  The limits of log-ratios , 2004 .

[75]  R. Elledge,et al.  Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome , 2004, Breast Cancer Research.

[76]  J. Thiery,et al.  Wide metastatic spreading in infiltrating lobular carcinoma of the breast. , 2004, European journal of cancer.

[77]  Paul J. van Diest,et al.  Biologic correlates of 18fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography , 2002 .

[78]  A. De Benedetti,et al.  Clinical outcome in stage I to III breast carcinoma and eIF4E overexpression. , 1998, Annals of Surgery.

[79]  A. Howell,et al.  A comparison of the metastatic pattern of infiltrating lobular carcinoma and infiltrating duct carcinoma of the breast. , 1984, British Journal of Cancer.

[80]  Jedd D. Wolchok,et al.  The future of cancer treatment: immunomodulation, CARs and combination immunotherapy , 2016, Nature Reviews Clinical Oncology.

[81]  Carsten Denkert,et al.  Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[82]  S. Rizvi,et al.  Invasive lobular carcinoma of the breast: should this be regarded as a chronic disease? , 2010, International journal of surgery.

[83]  L. Bassett,et al.  Invasive lobular carcinoma of the breast: spectrum of mammographic, US, and MR imaging findings. , 2009, Radiographics : a review publication of the Radiological Society of North America, Inc.